康達新材(002669.SZ):控股股東擬增持3000萬元-6000萬元公司股份
格隆匯2月7日丨康達新材(002669.SZ)公佈,公司於2024年2月7日收到公司控股股東唐山金控產業發展集團有限公司(簡稱“唐控產發集團”)發來的吿知函,基於對公司長期投資價值的認可,以及對公司未來持續穩定發展的信心,切實維護廣大投資者權益和資本市場穩定,唐控產發集團計劃擬自公吿披露之日起6個月內,以不低於3,000萬元人民幣,且不超過6,000萬元人民幣通過深圳證券交易所交易系統允許的方式,包括但不限於集中競價和大宗交易等方式增持公司股份。本次增持計劃不設定價格區間,唐控產發集團將根據公司股票價格波動情況及資本市場整體趨勢,擇機實施增持計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.